- Oops!Something went wrong.Please try again later.
GlaxoSmithKline plc GSK one of the largest health care companies, reshaped its business following the March 2015 completion of the three-part, inter-conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses. Under the deal, Glaxo sold its oncology assets to Novartis and acquired Novartis’ Vaccines business (excluding influenza vaccines). Glaxo has created a joint venture (“JV”) with Pfizer earlier in 2019, thereby combining their consumer healthcare unit.
Following the completion of the deal, the UK-based company now focuses on its three core businesses – Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products). However, Glaxo is currently focusing on its core assets and divesting non-core assets.
Meanwhile, like many of its peers, Glaxo is facing challenges in the form of COVID-19 restrictions, stiff competition, genericization and pricing pressure. In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers.
Glaxo’s performance has been mixed so far, with the company’s earnings missing expectations in two of the trailing four quarters, while beating the same once and meeting once. Overall, the company has delivered an average positive surprise of 13.21%.
Currently, Glaxo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Glaxo reported core earnings of $1.00 per American depositary share in the third quarter of 2021, which beat our consensus estimate of 80 cents. Core earnings were up 10% year over year at constant exchange rate (“CER”).
Revenues Beat: Revenues were up 10% year over year at CER to $12.4 billion (£9.1 billion). Revenues also beat the Zacks Consensus Estimate of $11.92 billion.
Key Stats: Sales in Vaccines segment increased 13% at CER while Consumer Healthcare sales increased 8%. Pharmaceuticals sales were also up 10% at CER. The Respiratory segment increased 33% at CER. HIV product sales were up 8% at CER. Shingrix sales were up 41%.
2021 Guidance: Glaxo improved its previous guidance. It expects adjusted EPS to decline by a by 2% to 4% at CER, year over year, compared to mid to high-single digit percentage previously in 2021.
Share Price Impact: Shares were up 0.3% in pre-market trading.
Check back later for our full write up on GSK earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline plc (GSK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research